Supply Chain Manager
We are currently seeking an experienced, talented and highly analytical Supply Chain Manager to join our Finance team.
Using lasers to paint a high-definition picture of the body’s COVID-19 immune response
Biosensing firm Adarza BioSystems is getting ready to launch its Ziva protein detection platform, though a little later than originally expected and including a new application.
In February, the firm raised $25 million in Series D funding and planned a summer release of its platform. But like many other companies, Adarza found itself having to shift its strategy as the SARS-CoV-2 pandemic shut down non-essential businesses across the economy. Instead of launching the system with its planned focus on immuno-oncology and neurology, the firm has moved to use its technology for immune profiling research supporting work like SARS-CoV-2 vaccine development.
Adarza Shifts Focus to SARS-CoV-2 in Anticipation of Protein Biosensor Launch
Biosensing firm Adarza BioSystems is getting ready to launch its Ziva protein detection platform, though a little later than originally expected and including a new application.
In February, the firm raised $25 million in Series D funding and planned a summer release of its platform. But like many other companies, Adarza found itself having to shift its strategy as the SARS-CoV-2 pandemic shut down non-essential businesses across the economy. Instead of launching the system with its planned focus on immuno-oncology and neurology, the firm has moved to use its technology for immune profiling research supporting work like SARS-CoV-2 vaccine development.
Adarza’s Ziva provides window into immune response to COVID-19 and other pathogens
Adarza Biosystems Inc.’s Ziva platform can simultaneously detect hundreds of proteins, antibodies, or substrates from a single drop of blood, plasma or serum, providing insight into an individual’s immune response. That could be critical for both surveillance and diagnostic purposes as the nation prepares for a likely second wave of the novel coronavirus in the fall when multiple respiratory pathogens will be circulating.
St. Louis biotech startup raises $25M as it prepares for commercialization
Adarza BioSystems said the funding will help it prepare for commercialization of its ZIVA platform, a biological testing device designed to assist researchers with disease profiling and drug development.
Adarza raises $25 million, moves toward commercialization
Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.
Adarza BioSystems Raises $25 Million in Series D Funding to Launch Platform for Research and Drug Development
Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3×5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney.
Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.
Adarza BioSystems to reveal ZIVA platform at AAI 2019
Adarza Biosystems, Inc. announced today that it will reveal its new protein multiplex instrument ZIVA at Immunology 2019, the annual meeting of the American Association of Immunologists (AAI) from May 9 – 13. Using a simple, time-saving workflow, the new automated system can simultaneously measure, analyze and report on up to 200 biomarkers.
Home Sweet Home: Adarza Settles into New Facility
Agreement gives Horizon exclusive right to supply services on Ardaza’s multiplex label-free immunoassay technology.
St. Louis Business Journal: St. Louis biotech startup to launch products in 2019
Once Adarza’s products launch in the second quarter of 2019, it will be one of a handful of local life sciences startups to have done so.